JMJD6 and neoplasm: Intriguingly, SKLB325 treatment and JMJD6 deficiency exerted a remarkable reduction in tumor growth relative to that of the sunitinib‐treated 786‐O cell‐SR or naive 786‐O cell‐SR mice, as quantified by serial bioluminescence signals (Figure 7H).